📊 FBIOP Key Takeaways
Is FBIOP a Good Investment? Thesis Analysis
Fortress Biotech exhibits severe operational losses (-138.7% operating margin) with negative free cash flow of -$53.2M, indicating the company is burning cash despite modest revenue growth of 4.6%. The disconnect between negative operating income and positive net income raises concerns about sustainability, and the company's cash runway will be critical to monitor given ongoing operational cash burn.
Why Buy FBIOP? Key Strengths
- Strong liquidity position with $86.2M in cash and 2.19x current ratio providing near-term operational runway
- Positive net margin of 22.8% and growing net income (+17.7% YoY) suggest potential profitability improvement trajectory
- Moderate leverage at 0.86x debt-to-equity ratio with reasonable balance sheet structure
FBIOP Investment Risks to Consider
- Severe operating losses of -$65.4M with operating margin of -138.7% indicating core business is unprofitable at scale
- Significant negative free cash flow of -$53.2M (-112.8% FCF margin) means the company is burning through cash reserves at an unsustainable rate
- Operating cash flow negative at -$53.2M while net income is positive suggests earnings quality concerns and potential non-cash gains masking operational deterioration
- Cash burn rate of approximately $53M annually means current $86.2M cash balance provides less than 2 years of runway without achieving positive operations
Key Metrics to Watch
- Operating cash flow trend and path to cash flow breakeven
- Cash runway and burn rate relative to milestone achievements
- Operating margin progression and evidence of cost control initiatives
- Revenue growth acceleration needed to reach profitability at current cost structure
FBIOP Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 2.19x current ratio provides a solid financial cushion.
FBIOP Profitability Ratios
FBIOP vs Healthcare Sector
How Fortress Biotech, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is FBIOP Overvalued or Undervalued?
Based on fundamental analysis, Fortress Biotech, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
FBIOP Balance Sheet & Liquidity
FBIOP 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Fortress Biotech, Inc.'s revenue has grown significantly by 34% over the 5-year period, indicating strong business expansion. The most recent EPS of $-8.47 indicates the company is currently unprofitable.
FBIOP Growth Metrics (YoY)
FBIOP Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $14.6M | $5.9M | $0.11 |
| Q2 2025 | $14.9M | $4.9M | $0.02 |
| Q1 2025 | $13.0M | -$10.6M | $-0.48 |
| Q3 2024 | $14.6M | -$5.0M | $-0.76 |
| Q2 2024 | $14.9M | -$10.9M | $-0.73 |
| Q1 2024 | $12.2M | -$15.4M | N/A |
| Q3 2023 | $15.3M | -$5.0M | $-0.94 |
| Q2 2023 | $17.0M | -$21.4M | $-0.24 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
FBIOP Capital Allocation
FBIOP SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Fortress Biotech, Inc. (CIK: 0001429260)
📋 Recent SEC Filings
❓ Frequently Asked Questions about FBIOP
What is the AI rating for FBIOP?
Fortress Biotech, Inc. (FBIOP) has an AI rating of SELL with 75% confidence, based on fundamental analysis of SEC EDGAR filings.
What are FBIOP's key strengths?
Claude: Strong liquidity position with $86.2M in cash and 2.19x current ratio providing near-term operational runway. Positive net margin of 22.8% and growing net income (+17.7% YoY) suggest potential profitability improvement trajectory.
What are the risks of investing in FBIOP?
Claude: Severe operating losses of -$65.4M with operating margin of -138.7% indicating core business is unprofitable at scale. Significant negative free cash flow of -$53.2M (-112.8% FCF margin) means the company is burning through cash reserves at an unsustainable rate.
What is FBIOP's revenue and growth?
Fortress Biotech, Inc. reported revenue of $47.2M.
Does FBIOP pay dividends?
Fortress Biotech, Inc. pays dividends, with $0.5M distributed to shareholders in the trailing twelve months.
Where can I find FBIOP SEC filings?
Official SEC filings for Fortress Biotech, Inc. (CIK: 0001429260) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is FBIOP's EPS?
Fortress Biotech, Inc. has a diluted EPS of $0.14.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is FBIOP a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, Fortress Biotech, Inc. has a SELL rating with 75% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is FBIOP stock overvalued or undervalued?
Valuation metrics for FBIOP: ROE of 19.2% (sector avg: 15%), net margin of 22.8% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy FBIOP stock in 2026?
Our dual AI analysis gives Fortress Biotech, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is FBIOP's free cash flow?
Fortress Biotech, Inc.'s operating cash flow is $-53.2M, with capital expenditures of $0.0. FCF margin is -112.8%.
How does FBIOP compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 22.8% (avg: 12%), ROE 19.2% (avg: 15%), current ratio 2.19 (avg: 2).